European researchers developed innovative therapeutic solutions for the treatment of primary immune deficiencies (PIDs). These ground-breaking medicinal products promise to provide clinical benefit to otherwise incurable diseases.
PIDs are rare inherited disorders of the immune system caused by mutations in genes required for the development and/or function of immune cells. Patients are prone to infections, autoimmunity and cancer with haematopoietic stem cell (HSC) transplantation from healthy donors being the treatment of choice. However, in the absence of a compatible donor, HSC transplantation is of limited use and often associated with complications.
Further details: Cell therapy for immunodeficiency